Executive Summary
CMS proposed dropping the 14-year-old Coverage with Evidence Development mandate for symptomatic TAVR and extending Medicare coverage to asymptomatic severe aortic stenosis, a regulatory shift built on EARLY TAVR that hands Edwards Lifesciences the year's biggest tailwind and pulls American practice toward the ESC 2025 posture on early intervention. The proposal also permits single-operator TAVR without a cardiac surgeon, prompting STS President Vinay Badhwar to flag concerns about heart-team integrity. A frailty-adjusted 10-year single-center cohort (N=1258, 114 matched pairs) showed SAVR survival superior to TAVI (HR 0.16, P=0.005), and a Y-incision annular enlargement series demonstrated larger effective orifice areas and zero patient-prosthesis mismatch versus 20.1% with TAVR, complicating the expansion case at exactly the moment CMS broadens it.
- [NOTABLE] CMS will allow chart-review triage and a single TAVR operator (interventional cardiologist OR surgeon), with no CED for symptomatic patients — public comment closes July 15 (TCTMD).
- STS publicly opposes the loss of CED and the demotion of surgeons on the heart team, calling the proposal misaligned with patient safety (Cardiovascular Business).
- Redo-SAVR carried 8.9% 30-day mortality vs 0% for valve-in-valve TAVR with bioprosthetic valve fracture in a propensity-matched 128-patient single-center series (JTCVS Structural).
- NT-proBNP rise at 4 weeks post-TTVI predicted long-term mortality independent of procedural success, sharpening surveillance after tricuspid intervention (JACC Advances).
- PASCAL and MitraClip G4 delivered comparable 30-day MR ≤2+ rates (92.3% vs 92.1%) in 150 propensity-matched primary MR patients from OCEAN-Mitral (Cath Cardiovasc Interv).
What to watch: The CMS comment period closes July 15 with a final NCD expected in September; STS, ACC, and SCAI letters in the next four weeks will shape whether the surgeon requirement survives.
Aortic Valve (TAVR/TAVI)
The CMS proposal is the most consequential US aortic policy shift since the original 2012 NCD, and it lands on top of fresh data that cuts both ways. CMS will extend coverage to asymptomatic severe AS under a CED paradigm while removing CED for symptomatic patients — a structure that codifies EARLY TAVR's signal but stops short of the ESC 2025 Class IIa endorsement for early intervention in all low-risk asymptomatic severe AS. ACC/AHA 2020 had confined early intervention to specific subgroups — very severe AS, elevated BNP, abnormal exercise test — and the CMS asymptomatic CED is built on data CMS itself characterizes as "promising but incomplete," particularly in preserved-LVEF patients.
The countervailing evidence dropped the same week: a single-center 10-year cohort (N=1258) with comprehensive frailty, cognitive, and nutritional adjustment found SAVR superior for long-term survival (HR 0.16, 95% CI 0.49–0.58, P=0.005) after 1:1 matching of 114 pairs — single-center, retrospective, but adjusted beyond STS-PROM alone. ACC/AHA 2020 favors SAVR under 65; ESC 2025 raised that floor to under 70. [NOTABLE] A Y-incision annular enlargement SAVR cohort (N=70 vs 292 TAVR) delivered effective orifice area 2.7 vs 1.9 cm², mean gradient 5 vs 9.5 mmHg, zero severe PPM vs 20.1% at 24–36 months. These hemodynamic data argue the age floor should hold — and they matter most for the asymptomatic patients CMS just brought into coverage, who are younger and will outlive their valves.
Other aortic signals: a 695-patient TAVR series found cerebral embolic protection reduced postoperative stroke/TIA from 2.9% to 0.4% in BAV, valve-in-valve, or calcium score >1000 anatomy after propensity matching. Subclinical leaflet thrombosis ML modeling identified bicuspid anatomy and perioperative hematological shifts as dominant predictors (AUC 0.84–0.89). A 10-year explant series confirmed 13% mortality for cardiac surgery after prior TAVR, with TAVR explant the most common and most morbid scenario — a direct warning as CMS broadens access to younger asymptomatic patients. ESC 2025 explicitly flags THV explantation mortality at 12–17% and mandates CT-based lifetime management planning at the index procedure; ACC/AHA 2020 is less prescriptive on this point.
Mitral Valve (MitraClip, PASCAL, TMVR)
PASCAL and MitraClip G4 show equivalent 30-day outcomes for primary MR. The OCEAN-Mitral registry compared 150 PASCAL cases against 679 MitraClip cases with propensity matching and found MR ≤2+ in 92.3% vs 92.1%, device success 95.0% vs 92.1%, clinical success 93.5% vs 87.8% — all non-significant. Single leaflet device attachment occurred once with PASCAL but was successfully retrieved. The registry is non-randomized and short-term; durability and structural performance at 2–5 years remain unresolved for both platforms. ACC/AHA 2020 and ESC 2025 both rate TEER as Class IIa for primary MR at high surgical risk, subordinate to surgical repair, and these 30-day data do not change that hierarchy.
A separate single-center series of mitral surgery after prior TAVR (N=19) reported 26.3% 30-day mortality, with TAVR explant required in over half — an operational warning as the structural population accumulates and younger patients enter coverage. CT analysis in 125 TAVR patients with baseline ≥3+ MR found inferior papillary muscle displacement independently predicted failed MR improvement (OR 5.63), useful pre-procedural anatomic intelligence when deciding whether TAVR alone will address a patient's MR burden.
Tricuspid Valve (TriClip, TTVR)
NT-proBNP dynamics carry independent prognostic weight after transcatheter tricuspid intervention. A TTVI cohort stratified by baseline NT-proBNP tertiles found higher baseline levels and rising NT-proBNP at 4 weeks independently predicted long-term mortality, while neither correlated with NYHA improvement — a patient can feel better and still be dying. The biomarker reflects residual myocardial stress rather than procedural success, a critical nuance as ESC 2025 elevates transcatheter TR treatment to Class IIa, LOE A for high-risk symptomatic severe TR. ACC/AHA 2020 carries no recommendation for transcatheter TR therapy; the ESC 2025 surgical upgrades — Class I for symptomatic severe primary TR — remain unmirrored in US guidelines. The gap is widening. Real-world EVOQUE data continues to show technical success above 98% with 30-day mortality near 3%, but biomarker trajectories like these will increasingly determine who actually benefits. Patient selection — not device performance — is the next frontier.
Surgical vs. Transcatheter Comparisons
The redo-AVR question sharpened this week. A 128-patient propensity-matched series compared redo-SAVR against valve-in-valve TAVR with bioprosthetic valve fracture and found ViVBVF delivered greater gradient reduction (-26.0 vs -17.4 mmHg) and lower adjusted 30-day mortality (0% vs 8.9%), with more frequent pacemaker implantation. Single-center, retrospective, modest sample — but the hemodynamic and safety signals are real. ESC 2025 acknowledges TAV-in-SAV as a viable strategy provided lifetime management is planned at the index procedure; ACC/AHA 2020 is more cautious on redo transcatheter sequencing. Set against the frailty-adjusted 10-year SAVR survival advantage published this week, the field is converging on a familiar truth: native AVR favors surgery in low-risk durable patients; redo favors transcatheter when anatomy permits.
Preprint Highlights
A randomized trial protocol from Colorado will test commercially available mHealth fitness programming against attention control in 200 TAVR patients on cardiac rehab waitlists, with daily step count, VO2max, and KCCQ as endpoints. Cardiac rehabilitation participation after TAVR remains abysmal; if commercial wearables move the needle, the structural population gets a cheap durable add-on. Hybrid type I effectiveness-implementation design; results will not arrive quickly.
Device & Technology
A computational modeling study found post-TAVI annular eccentricity disrupts coherent helical flow, raising relative residence time and simulated thrombus burden — a biology-independent geometric contributor to subclinical leaflet thrombosis. This dovetails with the ML analysis identifying bicuspid anatomy as the dominant SLT predictor and supports individualized post-procedural anticoagulation in elliptical anatomies. A narrative review of nitinol durability in self-expanding devices ran without abstract in JTD this week. Ascending aorta dilation post-TAVR: a 115-patient series with intermediate follow-up found aortic size did not progress meaningfully, with only 2 patients requiring aortic intervention — reassuring data for the moderately dilated cohort, though BAV patients ran larger.
Regulatory & Policy
The proposed CMS TAVR decision memo reshapes US structural practice along five axes: drop CED for symptomatic AS, add CED-covered asymptomatic AS, permit chart-review triage, allow single-operator TAVR, and revise volume thresholds (≥20 transcatheter valve procedures annually, ≥15 TAVR). The TCTMD breakdown notes the asymptomatic CED is built on EARLY TAVR data CMS characterizes as "promising but incomplete," especially in preserved-LVEF patients. [NOTABLE] STS President Vinay Badhwar publicly stated the society is "disappointed" the proposal does not protect the heart team or preserve evidence-informed decisions. SCAI member surveys split: 38.4% supported single-operator TAVR, 59.3% opposed continued CED for all procedures. ACC is reserving formal comment until July 15. The Alliance for Aging Research, which lobbied for the change, called it "transformative." The proposal aligns US policy toward — though not fully with — the ESC 2025 stance favoring earlier intervention; it does not adopt the ESC's age-based SAVR preference thresholds or its lifetime management planning requirements.
Industry & Market
Edwards is the unambiguous beneficiary. The company sponsored EARLY TAVR, holds the only FDA-approved asymptomatic AS indication (Sapien 3, May 2025), and requested the CMS reconsideration in December 2025. Citeline characterized the memo as a "clear win" for Edwards while regurgitation players remain in coverage limbo. Medtronic's Evolut platform benefits indirectly, but Boston Scientific's Acurate Neo2, Abbott's tricuspid franchise, and the aortic regurgitation entrants (JenaValve, J Valve, Anteris) gain nothing from this NCD.
Financial Analysis
The market reaction is paradoxical. Edwards hit a 52-week high on Monday's news, then sold off on Tuesday as the broader medtech sector fell hard — Boston Scientific shed 4.2%, Medtronic 3.9%, Abbott 2.3%. The Edwards CEO sold $45,982 of stock under a 10b5-1 plan on the move higher. The bull case rests on volume expansion to asymptomatic severe AS, which could add 20–30% to addressable patients per analyst commentary, while bears point out CED still applies to the new indication, slowing immediate uptake. The deeper issue: the same week CMS broadened access, peer-reviewed data showed SAVR superior at 10 years after frailty adjustment and SAVR + Y-AAE delivering markedly better hemodynamics than TAVR. Markets don't read JTCVS Structural. They will eventually.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $86.68, down $1.90 (-2.14%); 6-month change +2.22%; 52-week range $72.30–$89.60
- Market cap: $49.9B; trailing P/E 46.85; forward P/E 25.74; beta 0.87
- Analyst target: $96.92 (range $84–$110, 26 analysts); consensus Buy
- Next earnings: July 23, 2026; EPS est $0.74; revenue est $1.70B
EW touched a 52-week high Monday on the CMS memo before pulling back with the medtech complex. The asymptomatic AS expansion is the single most important regulatory catalyst for the franchise in over a decade, but CED requirements will throttle near-term volume. CEO Zovighian's 523-share sale was under a pre-scheduled 10b5-1 plan and is not a directional signal.
Medtronic (MDT)
- Close: $78.14, down $3.18 (-3.91%); 6-month change -19.42%; 52-week range $73.31–$106.33
- Market cap: $100.3B; trailing P/E 20.73; forward P/E 12.19; beta 0.60
- Analyst target: $98.00 (range $78–$121, 26 analysts); consensus Buy
- Next earnings: August 18, 2026; EPS est $1.39; revenue est $9.55B
Evolut benefits from the CMS expansion alongside Sapien, but MDT continues to underperform on broader medtech concerns. The structural heart franchise is a single line within a diversified portfolio under restructuring pressure.
Abbott (ABT)
- Close: $88.50, down $2.12 (-2.34%); 6-month change -28.46%; 52-week range $81.97–$139.06
- Market cap: $154.2B; trailing P/E 24.79; forward P/E 14.61; beta 0.62
- Analyst target: $116.54 (range $92–$135, 24 analysts); consensus Buy
- Next earnings: July 16, 2026; EPS est $1.28; revenue est $12.53B
Abbott's tricuspid TriClip franchise was unaffected by the TAVR memo, and the stock continues to grind lower on broader concerns. The ESC 2025 elevation of transcatheter TR to Class IIa, LOE A remains the structural tailwind that has yet to translate into sustained share performance.
Boston Scientific (BSX)
- Close: $44.95, down $1.97 (-4.20%); 6-month change -53.23%; 52-week range $44.79–$109.50
- Market cap: $66.8B; trailing P/E 18.81; forward P/E 12.07; beta 0.56
- Analyst target: $77.10 (range $55–$106, 30 analysts); consensus Strong Buy
- Next earnings: July 29, 2026; EPS est $0.83; revenue est $5.38B
BSX has lost over half its value in six months. The Acurate Neo2 aortic platform did not gain from the CMS move, and the structural heart pipeline (Sentinel CEP, mitral programs) remains a subsidiary contributor to a stock whose collapse is being driven by issues beyond the valve franchise.
Anteris Technologies (AVR.AX)
- Close: A$13.60, up A$1.07 (+8.54%); 6-month change +91.55%; 52-week range A$4.68–A$13.85
- Market cap: A$1.3B; forward P/E -6.24; beta 0.73
- Analyst target: A$13.00 (1 analyst)
Anteris rallied sharply alongside the Edwards news, with the DurAVR program seen as an indirect beneficiary of a US market more receptive to early intervention. The stock has nearly doubled in six months on pipeline optimism without a near-term commercial catalyst.
Market outlook: The medtech sell-off Tuesday was sector-wide and macro-driven; the Edwards-specific catalyst is real but throttled by CED. The structural heart investment thesis still depends on durability data that won't read out for years. Today's published evidence — SAVR superiority at 10 years, Y-AAE hemodynamics, post-TAVR explant morbidity — argues for caution on the lifetime management story that underwrites high-multiple valuations.
Clinical Trial Updates
The Colorado Cardio Heart Connect trial protocol is the notable enrollment opportunity: 200 post-TAVR patients on cardiac rehab waitlists, randomized 1:1 to commercial mHealth fitness vs attention control, with daily steps, VO2max, and KCCQ at 8 weeks and 12 months. CMS coverage expansion will pressure systems to find scalable post-procedural recovery models; this trial speaks directly to that need.
Social & Conference Highlights
Cardiac Wire circulated 10-year TAVR durability data this week, dovetailing with the JTCVS frailty-adjusted survival analysis. The structural heart Twitter/X commentary has split predictably: interventional voices celebrating expanded access, surgical voices pointing to durability and explant morbidity. Watch for Vinay Badhwar's STS-coordinated commentary in the July 15 comment window.
The next four weeks will decide whether US structural practice converges with ESC 2025 or stays anchored to a heart-team model that protects surgical input. Public comment closes July 15; the final CMS NCD lands in September. The peer-reviewed durability literature will keep arriving, indifferent to either deadline.
— E. Nolan Beckett, MD
The Valve Wire